Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

The evidence is not clear: Rheumatic diseases, drugs, and COVID-19

Key clinical point: For rheumatologists, quality evidence on COVID-19 is in short supply.

Major finding: Over 1,700 articles encompassing COVID-19, rheumatic diseases, and drugs for such diseases have been published.

Study details: PubMed search from Jan. 1, 2019, to June 24, 2020.

Disclosures: No sponsor was declared, and no conflicts of interest were reported.

Citation:

Kroon FPB et al. Ann Rheum Dis. 2020 Aug 12. doi: 10.1136/annrheumdis-2020-218483.